摘要
目的探讨丹参注射液联合地奥心血康胶囊治疗冠状动脉粥样硬化性心脏病(简称冠心病)心绞痛的临床疗效。方法选取河北省秦皇岛市第二医院2018年10月至2020年10月收治的冠心病心绞痛患者140例,按随机数字表法分为对照组(69例)与观察组(71例)。对照组在常规治疗基础上加用地奥心血康胶囊,观察组在对照组基础上联用丹参注射液,均连续治疗2周。结果治疗后,两组患者低密度脂蛋白胆固醇、总胆固醇、三酰甘油代谢水平均明显降低,高密度脂蛋白胆固醇代谢水平均明显升高,且观察组变化幅度明显高于对照组(P<0.05);血流动力学指标高切全血黏度、血浆比黏度、血小板黏附率均明显降低,且观察组降低幅度明显高于对照组(P<0.05);炎性因子C反应蛋白、白细胞介素6、肿瘤坏死因子-α、同型半胱氨酸水平均明显降低,且观察组降低幅度明显高于对照组(P<0.05);血清趋化因子、Ⅰ型胶原羧基末端肽、基质金属蛋白酶9、基质金属蛋白酶2水平均明显降低,且观察组降低幅度明显高于对照组(P<0.05);中医证候积分均明显降低,且观察组降低幅度明显高于对照组(P<0.05);观察组治疗总有效率为95.77%,明显高于对照组的85.51%(P<0.05);对照组与观察组患者治疗期间不良反应发生率相当(7.25%比9.86%,χ2=0.305,P=0.581)。结论丹参注射液联合地奥心血康胶囊可有效抑制冠心病心绞痛患者的临床症状,改善血脂代谢水平,降低血清炎性因子水平,且治疗安全性良好。
Objective To investigate the clinical efficacy of Danshen Injection combined with Di′ao Xinxuekang Capsules in the treatment of patients with coronary heart disease(CHD)and angina pectoris.Methods A total of 140 patients with CHD and angina pectoris admitted to the Second Hospital of Qinhuangdao from October 2018 to October 2020 were selected and divided into the control group(69 cases)and the observation group(71 cases)by the random number table method.The patients in the control group were treated with Di′ao Xinxuekang Capsules on the basis of conventional treatment,and the patients in the observation group were treated with Danshen Injection on the basis of the treatment in the control group.Both group were treated for two weeks.Results After treatment,the metabolic levels of low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and triacylglycerol(TG)in the two groups significantly decreased,the metabolic level of high-density lipoprotein cholesterol(HDL-C)in the two groups significantly increased,and the change in the observation group was more significant(P<0.05).After treatment,the levels of hemodynamic indexs such as high-shear whole blood viscosity,ratio of viscosity and platelet adhesion rate in the two groups significantly decreased,and the decrease in the observation group was more significant(P<0.05).After treatment,the levels of inflammatory factors such as C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and homocysteine(Hcy)in the two groups significantly decreased,and the decrease in the observation group was more significant(P<0.05).After treatment,the levels of serum fractalkine such as CX3CL1,carboxy-terminal telopeptide of typeⅠcollagen(ICTP),matrix metalloproteinase-9(MMP-9)and matrix metalloproteinase-2(MMP-2)in the two groups significantly decreased,and the decrease in the observation group was more significant(P<0.05).After treatment,the traditional Chinese medicine syndrome score in the two groups significantly decreased,and the decrease in the observation group was more significant(P<0.05).The total effective rate of treatment in the observation group was 95.77%,which was significantly higher than 85.51%in the control group(P<0.05).During the treatment,the incidence of adverse drug reactions in the observation group was comparable to that in the control group(7.25%vs.9.86%,χ2=0.305,P=0.581).Conclusion Danshen Injection combined with Di′ao Xinxuekang Capsules can effectively relieve the clinical symptoms of patients with CHD and angina pectoris,improve the level of blood lipid metabolism,reduce the level of serum inflammatory factors,and the treatment is safe.
作者
石小平
赵飞
SHI Xiaoping;ZHAO Fei(The Second Hospital of Qinhuangdao,Qinhuangdao,Hebei,China 066600;Xianghe County People's Hospital,Langfang,Hebei,China 065400)
出处
《中国药业》
CAS
2023年第9期98-102,共5页
China Pharmaceuticals
基金
河北省中医药管理局科研计划项目[2021380]。
